ESTRO 2023 - Abstract Book

S878

Digital Posters

ESTRO 2023

Conclusion We recommend a heightened awareness of the dangers of delaying cancer presentation and care in healthcare policies and resource allocation and at the same time, encourage patient’s confidence in their ability to seek care. With the resurgence of new COVID-19 variants and case numbers worldwide and in Singapore, this study focuses upon the need to be aware of the exigencies of other clinical groups in resource utilization. It would be instructive to compare this study with future long term follow up to investigate the trajectory of our cancer care delivery, as well as survival outcomes.

PO-1096 Delay treatment profile in cancer patients referred to radiotherapy at a national referral hospital

S. Wirawan 1

1 Universitas Indonesia, Department of Radiation Oncology, Jakarta, Indonesia

Purpose or Objective Cancer is a very complex disease requiring a multidisciplinary approach in diagnostics and therapy. The duration of the diagnosis and treatment of cancer patients affect the outcome of these patients. Delay in treatment may be caused by the delay in referring physicians in primary health care and health care system delay in the commencement of the process of diagnosis and definitive therapy in cancer. Materials and Methods This study was a descriptive-analytical study using a mix of quantitative and qualitative methods to determine the incidence of data delays due to delays in therapy, doctor, and system delay in cancer patients who were referred to the Department of Radiotherapy at the national referral hospital in May to August for 2015 and evaluate the factors that influence the delay. Results There were 294 patients included in this study after obtaining informed consent. At the doctor's delay due to delayed treatment, of 62 patients referred from primary health care, 18 (29%) experienced a delay in referral. Delay in diagnosis occurred in 78 patients (26.5%). While the delay in treatment action occurred in 172 patients (58.5%). Of all patients,132 (45%) experienced doctor and system delays. Statistical analysis showed a significant correlation between the reference delay (p <0.01), late diagnosis (p <0.01), and delays in treatment measures (p <0.01) with a delay due to delayed therapy and the doctor system. Conclusion The high number of delays in cancer therapy in this study was found as a result of delays in doctors and systems, particularly the delay in diagnosis and treatment. P. Fossati 1 , M. Stock 2 , M. Pelak 3 , G. Martino 4,6 , S. Tubin 3 , J. Góra 5 , U. Mock 3 , M. Daniel 6 , P. Georg 3 , M. Mumot 6 , C. Reschl 6 , A. Carlino 7 , E. Hug 3 1 1) MedAustron Ion Therapy Center, 2) Karl Landsteiner University of Health Sciences, Radiation Oncology, Wiener Neustadt, Austria; 2 1) MedAustron Ion Therapy Center, 2) Karl Landsteiner University of Health Sciences, Medical Physics, Wiener Neustadt, Austria; 3 MedAustron Ion Therapy Center, Radiation Oncology, Wiener Neustadt, Austria; 4 MedAustron Ion Therapy Center, , Medical Physics, Wiener Neustadt, Austria; 5 ustron Ion Therapy Center, Medical Physics, Wiener Neustadt, Austria; 6 MedAustron Ion Therapy Center, Medical Physics, Wiener Neustadt, Austria; 7 MedAustron Ion Therapy Center, Medical physics, Wiener Neustadt, Austria Purpose or Objective MedAustron is a dual particle facility capable of delivering spot scanning particle therapy with both protons and carbon ions. From July 2019 to October 2022 350 patients have been treated using CIRT. The most common indications were inoperable bone and soft tissue sarcoma (103 pts), non SCC-H&N tumors (87 pts), re-irradiation (114 pts) and high risk PO-1097 Carbon ion radiotherapy (CIRT) at MedAustron: early clinical experience